StartUPDATES: New developments from healthcare startups
Check out news from healthcare startups including Carrum Health, Seven Bridges Genomics, Outcomes4Me and more.
Check out news from healthcare startups including Carrum Health, Seven Bridges Genomics, Outcomes4Me and more.
Check out news from healthcare startups including Truvian Sciences and Seven Bridges Genomics.
The Chicago-based startup company plans to use the funding to further growth of its product offering and integration with EHRs and genetic testing partners.
The new report, from the University of Pittsburgh Medical Center's Center for Connected Medicine, surveyed 101 representatives of hospitals and healthcare systems. Nine out of 10 respondents said they were providing genomic or genetic testing or planning to.
A Q&A with executives from Seven Bridges, a bioinformatics analysis business, highlights the company's work in the precision medicine sector.
Under the decision, Medicare patients with inherited cancer mutations such as BRCA will receive coverage for NGS testing. Drugs that treat BRCA-mutated breast and ovarian cancers include AstraZeneca's Lynparza and Pfizer's Talzenna.
Color vice president for research and scientific affairs Alicia Zhou explained that there is an ethical obligation to provide information on actionable genes, but costs and logistics have previously made doing so prohibitive.
To help cut down cancer disparities and deaths, OSF HealthCare recently announced that it will be expanding its genetic cancer risk assessment software into its Epic electronic health record for primary care practices.
Salt Lake City-based Myriad Genetics' GeneSight screening analyzes specific genes as a way to predict the effectiveness of 56 common medications for depression.
On the company's LunaDNA platform, a whole genome can be exchanged for 300 company shares, while 20 days of fitness data is equal to two shares.
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
The company, which was founded in 2014 by a team including genetics pioneer Leroy Hood, raised more than $50 million over its existence from investors including Maveron, Polaris Partners and ARCH Venture Partners.
Helix is responsible for sequencing the user's DNA and passing results to PerkinElmer, which will provide data analysis and interpretative services using the company's team of medical geneticists.
Burke joined the Mountain View, California-based chronic disease management company late last year after spending more than two decades at EHR giant Cerner.
These two announcements come after Deborah DiSanzo left her role as IBM Watson Health general manager last year.
The risks associated with ignoring genetic factors far exceed the complications of including them and going forward there will be more clinical trials having a genetic or precision medicine component to develop targeted therapies.